Depression is highly prevalent in patients with schizophrenia and is associated with significant clinical consequences, but there is no known biomarker for depression in schizophrenia. One of the putative neurochemical biomarkers for depression in major depressive disorder (MDD) is reduced cerebral concentration of myo-Inositol. We examined whether myo-Inositol levels provide a potential marker for depressive symptoms in schizophrenia similar to that in MDD and are informative regarding causal biological pathways underlying both depression and schizophrenia. We used proton magnetic resonance spectroscopy to examine myo-Inositol levels in the anterior cingulate cortex (ACC) in 59 schizophrenia spectrum disorder (SSD) patients and 69 matched community comparison participants. Participants completed the Maryland Trait and State Depression (MTSD) scale to measure symptoms of depression experienced around time of assessment ('State' subscale) and longitudinally ('Trait' subscale). Myo-Inositol in the ACC was negatively correlated with MTSD-Trait scores in both patients (ρ = − 0.336, p = 0.009) and community comparison samples (ρ = − 0.328, p = 0.006). Furthermore, patients with a diagnosis of schizoaffective disorder or a history of at least one major depressive episode had lower levels of myo-Inositol compared with schizophrenia patients without a current or past affective diagnosis (p = 0.012). Since reduced brain myo-Inositol is associated with MDD, myo-Inositol may be a biochemical marker of depressive mood symptoms across diagnostic boundaries. If confirmed, this finding may aid investigation of the pathophysiology and therapeutics of depression common between depression, schizophrenia and other psychiatric diagnoses.
INTRODUCTION
Depression and psychosis are two of the most common psychopathologies and are often co-morbid. Schizophrenia patients with depression have poorer quality of life, higher suicide risk and higher rate of re-hospitalization (Sim et al, 2004; Heilä et al, 1997; Sands and Harrow, 1999) . The clinical characteristics of depression in schizophrenia have been extensively studied from a clinical, but not neurobiological perspective (Siris, 2000; Buckley et al, 2009; Bermanzohn et al, 2000) . In the largest study of depression of schizophrenia, about 4000 schizophrenia patients were grouped as 'depressed' vs 'non-depressed'. Three-quarters maintained their grouping status after 2-3 years (Conley et al, 2007) , suggesting a trait-like property of depression in schizophrenia patients. Importantly, those who changed to nondepressed in 2-3 years improved in 91% of the functional outcomes assessed; but those who changed to depressed worsened in 94% of the function outcomes, suggesting that depression may be an important treatment target in schizophrenia. There is currently no known neurobiological marker that tracks the severity of depression in schizophrenia; such a marker may aid treatment development.
Decreased levels of myo-Inositol have been reported in (CSF) and post-mortem frontal cortex of patients with mood disorders (Barkai et al, 1978; Shimon et al, 1997) . Glial cells contain a high concentration of myo-Inositol (Brand et al, 1993; Griffin et al, 2002) . Myo-Inositol contributes to glial osmoregulatory functioning (Strange, 1992; Fisher et al, 2002) , as well as a wide range of other structural and signaling functions. Consistently, proton magnetic resonance imaging ( 1 H-MRS) studies of patients with major depressive disorder (MDD) report reduced levels of myo-Insoitol in prefrontal and anterior cingulate cortex (ACC; Frey et al, 1998; Coupland et al, 2005; Chen et al, 2014) . Conversely, positive clinical outcome in MDD is associated with increased myo-Inositol levels (Chen et al, 2014; Zheng et al, 2010) . These data indicate that reduced myo-Inositol in MDD is primarily associated with depression symptoms rather than being secondary to treatment. Furthermore, several small trials have suggested an antidepressant effect of inositol supplementation (Levine, 1997) . In bipolar disorder, some 1 H-MRS studies suggest frontal myo-Inositol is reduced in depressed periods and normal in euthymic periods, but these findings have been inconsistent and may be confounded by the use of mood stabilizers (reviewed in the study by Silverstone et al, 2005) .
Previous MRS studies in schizophrenia patients have generally shown no alterations in the concentration of myo-Inositol in cerebral gray matter (as reviewed in the study by Kim et al, 2005; Schwerk et al, 2014) . One postmortem study found a lower concentration of myo-Inositol in frontal cortex of patients with schizophrenia (Shimon et al, 1998) ; this was not replicated (Shapiro et al, 2000) , nor were altered levels of inositol found in CSF from schizophrenia patients (Levine et al, 1994) . Moreover, inositol supplementation failed to improve total PANSS scores in a small trial of schizophrenia patients (Levine, 1997) . However, these studies did not consider whether brain myo-Inositol was related to depression in schizophrenia patients, as would be suggested by studies in MDD. Although the subjective experience of depression is similar between psychotic and mood disorders (Chiappelli et al, 2014b) , there have been few studies to examine if the neurobiological correlates of depression also overlap. Therefore, we aimed to examine myo-Inositol in the context of depression in schizophrenia. We previously reported that patients with schizophrenia who have experienced greater frequency of depressive symptoms throughout their adult life had relatively preserved white matter microstructure (Chiappelli et al, 2014a) , providing some of the first neurobiological correlates for depression in schizophrenia. Here we extend this line of investigation by examining how brain myo-Inositol is related to current (state) and longitudinal (trait) symptoms of depression in schizophrenia spectrum disorders (SSDs) patients.
MATERIALS AND METHODS

Participants
This study included 59 persons with SSD (age range 19-62 years) and 69 age-and sex-matched community controls (age range 18-61 years). Not included in the sample were three participants (two SSD patients and one control) due to head movement and a technical problem with data retrieval, leading to inadequate imaging data, which were excluded prior to any statistical analysis. Diagnoses were confirmed with the Structured Clinical Interview for DSM-IV (SCID) in all participants. Major medical and neurological illnesses, history of head injury with cognitive sequelae, mental retardation, substance dependence within the past 6 months, or current substance abuse (except nicotine) were exclusionary in all participants. SSD patients were recruited from the outpatient clinics at the Maryland Psychiatric Research Center and neighboring mental health clinics. Among the SSD sample, 12 patients had a diagnosis of schizoaffective disorder, and 11 had a history of major depressive episodes. For a subgroup analysis, these 23 patients were defined as 'schizophrenia with a diagnostic mood component' group, in contrast to the remaining group of 36 patients as 'schizophrenia without a diagnostic mood component'. Except for 3 medication-free participants, all SSD patients were on antipsychotic medications, including 14 on clozapine, 4 taking a single typical antipsychotic, 23 taking a single atypical antipsychotic, and 15 taking a combination of antipsychotic medications. Twelve SSD patients in this sample were taking a mood stabilizer at the time of study, including eight on valproic acid, three on lamotrigine, and one on topiramate. Community comparison participants were recruited through media advertisements. Comparison participants had no family history of psychosis in two generations. Most of the comparison participants did not have Axis I diagnoses by SCID, although we did not exclude individuals with a current or past history of a mood disorder, to preserve some variation in depressive symptoms present in the community non-psychotic population. There were two participants in the community sample who had a history of bipolar disorder (one taking a mood stabilizer), and five had a diagnosis of a unipolar depressive disorder (two taking an antidepressant). Participants gave written informed consent approved by the University of Maryland Baltimore IRB.
Clinical data were available for all included participants. Symptoms of depression were measured using the Maryland Trait and State Depression (MTSD) scales, a self-report instrument that is completed in an interview setting. Factor analysis revealed that depression symptoms captured by MTSD in both schizophrenia patients and controls were segregated into two domains: trait and state depression. Trait depression reported by the patients through MTSD was distinct from their negative symptoms (Chiappelli et al, 2014b) . The MTSD assesses how frequently symptoms of depression were experienced in the week prior to assessment ('State' subscale) and throughout adult life ('Trait' subscale) (www.mdbrain.org/MTSD_instructions_and_scale.pdf). MTSD scores are reported as average response (scale 0-4) for all items. Overall psychiatric symptoms, including positive psychotic symptoms, were assessed with the item mean of the full 20-item brief psychiatric rating scale (BPRS) and mean of the BPRS psychosis subscale (Overall and Gorham, 1962) . The demographics and symptom information are shown in Table 1 .
ACC Magnetic Resonance Spectroscopy
All imaging was acquired using a Siemens 3 T TRIO MRI (Siemens, Erlangen, Germany) system equipped with a 32-channel phase array head coil. A 40 × 30 × 20 mm spectroscopic voxel was prescribed on the midsagittal slice and positioned parallel to the genu of the corpus callosum and scalp with the midline of the voxel corresponding to the middle of the genu of the corpus callosum ( Figure 1a ). This medial prefrontal/ACC area was targeted because of the extensive literature supporting its role in both depression and schizophrenia. Imaging studies suggest that the medial prefrontal/ACC is a critical component of neural networks that regulates mood and emotionally influenced behavior in depression (Sacher et al, 2012; Phillips et al, 2003) and also a critical region associated with cognitive and emotional impairment in schizophrenia (Fornito et al, 2009; Reid et al, 2010; Carter et al, 2001; Phillips et al, 2003) . Spectra were acquired using very short TE (VTE) phase rotation (PR) STEAM sequence: TR/TM/TE = 2000/10/6.5-ms, NEX = 128, 2.5-kHz spectral width, 2048 complex points, and phases: φ1 = 135°, φ2 = 22.5°, φ13 = 112.5°, φADC = 0° ( Wijtenburg and Knight-Scott, 2011; Wijtenburg et al, 2014) . A water reference (NEX = 16) was also acquired for phase and eddy current correction as well as quantification. A basis set of 19 metabolites was simulated using the GAVA software package (Soher et al, 2007) . The basis set was imported into LCModel (6.3-0I) and used for quantification (Provencher, 1993) . Correction for the proportion of the gray matter, white matter, and the CSF within each spectroscopic voxel was performed using SPM8 and in-house Matlab code (Gasparovic et al, 2006) . Only metabolites with Cramer Rao lower bounds (CRLB) o20% were included in statistical analyses. Spectra with LCModel reported linewidths (LW) 40.1 Hz and signal-to-noise ratio (SNR) o10 were excluded. Metabolite levels are reported in institutional units (i.u.). Previously, we have shown that the VTE PR-STEAM method produces excellent reproducibility as determined by a test-retest study (Wijtenburg et al, 2014) . There were no significant group differences in the quality of the spectra and metabolite fits. The mean (± SD) SNR was 35.6 ±7.0 for controls and 33.1 ± 8.1 for patients. The full width half maximum for controls was 0.037 ± 0.011 and for patients was 0.038 ± 0.013. The CRLB, measures of goodness-of-fit for metabolites, were as follows: myo-Inositol: 3.5 ± .61 vs 4.0 ± 1.1 (control vs patient, respectively; same below); glutamate: 4.7 ± 1.1 vs 5.3 ± 1.4; glutamate+glutamine (Glx): 5.0 ± 1.0 vs 5.5 ± 1.4; N-acetylaspartate (NAA) plus N-acetylaspartylglutamate (NAAG) (total NAA): 2.6 ± 0.7 vs 2.9 ± 0.8; glutathione (GSH): 7.6 ± 1.3 vs 8.5 ± 2.3; total choline: 4.6 ± 1.0 vs 5.0 ± 1.6; total creatine: 2.5 ± 0.6 vs 2.8 ± 0.8. Proportion of gray matter in the spectroscopic voxel did not significantly differ between patients and controls (t = 0.385, p = 0.701).
Data Analysis
Group comparisons for clinical and imaging measures were performed using t-tests and one-way ANOVA. Group categorical comparisons used two-sided χ 2 -tests. The distribution of MTSD data deviated from a normal distribution as determined by Kolmogorov-Smirnov tests, so correlation analyses were performed using Spearman's correlations. An omnibus linear multiple regression was performed to examine the relative contributions of depression, demographic variables, and medication use on myo-Inositol levels. All tests were two-tailed, with significance set to po0.05.
RESULTS
As reported previously (Chiappelli et al, 2014b) , SSD patients had greater levels than controls of both trait (mean ± SD: 1.21 ± 1.08 vs 0.55 ± 0.62, respectively, po0.001), and state (mean ± SD: 1.04 ± 0.99 vs 0.30 ± 0.40, respectively, po0.001) depression as measured with the MTSD (Table 1 ). There was no significant difference in ACC myo-Inositol levels between the SSD (6.84 ± 0.84) and community comparison (6.94 ± 0.60) samples (t = 0.80, p = 0.43; Figure 2a ). However, among the SSD sample, those participants with a diagnostic mood component (schizoaffective disorder or history of one or more major depressive episode) had a significantly lower level of myo-Inositol (6.50 ± 0.90) than the patient group without a diagnostic mood component (7.06 ± 0.74; t = 2.59, p = 0.012; Figure 2b ). Patients with a diagnostic mood component had significantly higher trait depression (mean ± SD: 1.71 ± 1.11 vs 0.88 ± 0.95, respectively, p = 0.003) though not state depression (mean ± SD: 1.34 ± 0.94 vs 0.85 ± 0.99, respectively, p = 0.07) compared with patients without a diagnostic mood component.
To examine how myo-Inositol levels may track depressive symptom severity, correlations between myo-Inositol and MTSD scores were examined in each sample independently. In the community comparison sample, myo-Inositol levels were significantly and inversely correlated with both MTSDTrait (ρ = − 0.328, p = 0.006) and MTSD-State (ρ = − 0.337, p = 0.005) scores. In the SSD, myo-Inositol was also inversely and significantly correlated with MTSD-Trait (ρ = − 0.336, p = 0.009) and MTSD-State (ρ = − 0.271, p = 0.038) scores. Using Bonferroni correction to control for multiple testing, only trait depression was statistically significant. Therefore, an inverse correlation between ACC myo-Inositol level and trait depression is a replicable finding across the two independent samples with significantly different levels of trait depression, with and without an SSD diagnosis (Figure 3) . After removing controls with any history of a mood disorder there was still a trend level, inverse relationship between myo-Inositol levels, and MTSD-State (ρ = − 0.243, p = 0.058) and MTSD-Trait (ρ = − 0.237, p = 0.064) in the community comparison sample.
To examine the effects of demographic variables or medication usage on the relationship between depression and myo-Inositol levels, a linear regression analysis was performed using myo-Inositol level as the outcome variable, and diagnosis (SSD versus community control), MTSD-Trait and MTSD-State scores, age, gender, smoking status (current smoker or nonsmoker), antidepressant use (current use or not), and mood stabilizer (current use or not) used as predictor variables. This regression model was significant (F(8,119) = 4.89, po0.001). MTSD-Trait scores remained a significant negative predictor of myo-Inositol levels (β = − 0.261, p = 0.035), however, MTSD-State scores were not (β = − 0.053, p = 0.68). Although highly correlated with each other, MTSD Trait and State scores had acceptable variance inflation factors (VIF) within this model (2.37 and 2.51, respectively); a frequently used 'rule of thumb' is that a VIF 45 represents unacceptable colinnearity (O'brien, 2007) . This model also indicated that age was positively correlated with myo-Inositol levels (β = 0.270, p = 0.001) and that use of a mood stabilizer was associated with lower myoInositol (β = − 0.229, p = 0.009). Diagnosis (SSD vs control) (β = 0.064, p = 0.52) and antidepressant use (β = 0.062, p = 0.51) were not significant predictors of myo-Inositol level. A separate linear regression analysis was conducted in the SSD sample alone, entering the same variables above with the exception of diagnosis and MTSD-State scores, but also including chlorpromazine dose equivalent of antipsychotic medication. This model was also significant (F(7,51) = 2.39, p = 0.034) with no important change in the slope estimating linear association of MTSD-Trait with myo-Inositol (β = − 0.285, p = 0.037), and current antipsychotic medication dosage showed no significantly independent effect on myo-Inositol (β = 0.025, p = 0.86).
There were no significant relationships between myoInositol and BPRS total scores (r = − 0.10, p = 0.44) or BPRS psychosis subscale (r = − 0.06, p = 0.67), suggesting that myo-Inositol levels were not significantly associated with psychosis symptoms in general, but were more specifically related to depression. Finally, the current MRS sequence also provides data on levels of the following prominent metabolites: glutamate, Glx, total NAA, glutathione, total creatine, and total choline. The relationship between these metabolites and depression, as a means to test for the specificity of the myo-Inositol finding, was explored (Table 2) . Giving the lack of a priori hypotheses, this exploratory analysis employed Bonferroni correction for 24 comparisons (6 MRS measures × 2 groups × state/trait depression or po0.0021). Glutamate, Glx, total NAA, glutathione, and total creatine were not significantly associated with depression in either groups (all p40.05 uncorrected). Interestingly, in SSD choline was negatively associated with trait depression (ρ = − 0.388, p = 0.002, significant after Bonferroni correction). Choline was also negatively correlated with trait depression in the community comparison sample (ρ = − 0.245, p = 0.045), though this was not significant. Therefore, among the metabolites measured by this MRS sequence, the relationship of myo-Inositol to depression is relatively specific and replicable across groups.
DISCUSSION
We found that depressive symptoms in SSD patients were associated with reduced levels of ACC myo-Inositol, a finding consistent with previous studies of patients with MDD. Interestingly, even in our community comparison sample, in which rates of depressive symptoms are overall low, the association between depression and reduced myo-Inositol was observed. This indicates that low levels of myo-Inositol may be a biomarker correlated with depressive symptoms across the current DSM diagnostic boundaries between mood and psychosis diagnoses.
The underlying mechanism linking myo-Inositol to depression in schizophrenia or MDD is unclear. Although neurons exhibit activity-dependent uptake of myo-Inositol (Uldry et al, 2004) , myo-Inositol is more concentrated in glial cells than neurons (Brand et al, 1993; Griffin et al, 2002) , and may be critical for glial osmoregulatory functioning (Strange, 1992; Fisher et al, 2002) . In neuro-inflammatory conditions, elevated myo-Inositol levels are presumed to reflect astrocyte and microglial activation (Chang et al, 2014 , Kirov et al, 2013 ; conversely, reduced myo-Inositol levels have been interpreted as evidence of astrocyte necrosis in neuromyelitis optica (Ciccarelli et al, 2013) . Several postmortem studies have found reduced density of glial cells (Ongür et al, 1998; Hamidi et al, 2004) and decreased concentration of protein markers specific to astrocytes in MDD (MiguelHidalgo et al, 2000; Miguel-Hidalgo et al, 2011; MiguelHidalgo et al, 2014) , providing a histological basis for interpreting reduced myo-Inositol levels in MDD as evidence of glial dysfunction (Coupland et al, 2005; Chen et al, 2014) . Analysis of post-mortem tissue has also implicated reduction in glial numbers in schizophrenia (Rajkowska et al, 2002; Stark et al, 2004) , though MRS studies, including this current study, have generally found no evidence of altered levels of myo-Inositol in schizophrenia Schwerk et al, 2014) . Stress-induced disruption of glial-neuronal interaction has recently been proposed as a mechanism to explain the cross-diagnostic impact of glial deficits on mood regulation (Edgar and Sibille, 2012) , a hypothesis that could potentially be expanded by integrating the osmoregulatory and cell signaling functions of myo-Inositol, and thereby present new opportunities for translational research in depression and schizophrenia.
The inositol pathway has been extensively studied for mechanistic insights into the therapeutic effects of mood stabilizers in bipolar disorder. Preclinical studies have shown that major mood stabilizers such as lithium, valproic acid, and carbamazepine all can reduce myo-Inositol levels (Williams et al, 2002) . Data from our samples were consistent with these findings, as current use of mood stabilizer was associated with significantly lower level of myo-Inositol in ACC when diagnosis and other clinical factors were controlled for (β = − 0.231, p = 0.008). However, use of mood stabilizers did not explain the observed association of myoInositol levels with depressive symptoms.
Several studies have found evidence that myo-Inositol level in frontal gray matter increases with age (Chang et al, 1996; Reyngoudt et al, 2012) . We replicated this, finding age to be positively correlated with myo-Inositol levels after controlling for other demographic variables (β = 0.273, p = 0.001). This finding was present in community controls (r = 0.374, p = 0.002) but was not significant in SSD patients (r = 0.220, p = 0.09); however, if patients taking mood stabilizers were excluded, the increase of myo-Inositol with age becomes more evident in patients (r = 0.337, p = 0.020). Other biomarkers previously described in schizophrenia, such as white matter integrity and cortical thickness (van Haren et al, 2011) , are typically shown to be reduced or impaired by disease and also usually decline with age. Thus, in the context of biomarker development, this opposite relationship of a biomarker with disease vs age is interesting, although the implication of this observation is currently unknown. A negative correlation was also found between trait depression and ACC choline levels, but only in the patients. Choline containing compounds measured with MRS (phosphocholine and glycerophosphocholine) are found in about twofold greater concentration in glia than neurons (Urenjak et al, 1993) , thus this finding may be consistent with the hypothesis that depression is particularly associated with glial dysfunction. Alternatively, choline levels are sometimes interpreted as a sign of membrane phospholipid turnover, which may be associated with cell proliferation and synaptic remodeling; this has been hypothesized to be the basis for the observation that antidepressant medications and electroconvulsive therapy increase choline levels (Ende et al, 2000; Sonawalla et al, 1999) , or prevent stress-induced reductions in choline (Czéh et al, 2001 ). This post-hoc finding requires replication; and if confirmed, future studies should examine the relationship between myo-Inositol and choline at the level of cellular and particular glial pathways.
A strength of this study was the use of the MTSD, which allows the measurement of depression symptoms over two temporal frames: the current load of symptoms, as well as the longitudinally experienced depressive symptoms reported by the patients. The principal finding of greater levels of depression associated with lower myo-Inositol was stronger for the trait-like experience of depressive symptoms than state depression, suggesting the utility of myo-Inositol as a marker that tracks a more stable, longitudinal aspect of psychopathology, as opposed to a state-dependent measure. Our prior work with this instrument suggested a similar factor structure in symptoms of depression between schizophrenia patients and a community comparison sample, and also found that the MTSD-measured depressive symptoms were distinct from negative symptoms (Chiappelli et al, 2014b) . The results here provide convergent validity that the experience of depression is comparable between schizophrenia and affective disorders, in that the neurobiological marker myo-Inositol tracks both in a similar manner. However, as this was a cross-sectional study, we cannot make conclusions regarding causal direction in the relationship between symptoms of depression and myo-Inositol. This finding is intriguing, as it hints at the biology involved in depression; at the same time, the correlations are relatively weak, accounting for about 11% of the variance in depression measured by the MTSD. This is not surprising because many genetic and psychological factors contribute to vulnerability to depression, with most likely acting independent of or upstream to myo-Inositol and its associated pathways. An additional limitation of this study was the wide range of medications used by participants. Although our analyses did not indicate that use of antidepressant or antipsychotic medications had a significant impact on the relationship between depression and myo-Inositol, it would be of interest to examine this relationship in a sample of medication-free participants. The finding regarding the impact of mood stabilizer use on myo-Inositol level is consistent with preclinical studies, but is based on a small sample of participants taking different types of mood stabilizers, and thus needs confirmation from a larger sample.
To our knowledge, this is the largest MRS study of cerebral myo-Inositol in schizophrenia and depression thus far.
The results indicate the potential use of myo-Inositol as a potential biomarker for depression in schizophrenia, and possibly across disorders; however, extensive research is needed to ascertain whether myo-Inositol can be developed into a clinically useful biomarker with appropriate sensitivity and specificity. Depression is a key factor contributing to the clinical heterogeneity of SSD. Further study of the inositol pathway may improve our understanding of clinical heterogeneity in schizophrenia at the level of neurobiological changes. If treatment targets upstream of myo-Inositol are identified, MRS myo-Inositol might be a useful measure to assess target engagement in preclinical and early stage human studies.
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